Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

NCT05903833 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT05903833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05903833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Lead sponsor
AGO Research GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2025
Completion date
October 30, 2029
Enrollment
42 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced vulvar cancer, metastatic vulva cancer, persistent vulvar cancer, recurrent vulvar cancer